tradingkey.logo

Amgen Says 24-Week Study Of Monthly Maritide In People With Type 2 Diabetes Showed Robust, Clinically Meaningful Reduction In Both HBA1C, Weight

ReutersJan 13, 2026 12:25 AM

- Amgen Inc AMGN.O:

  • AMGEN: 24-WEEK STUDY OF MONTHLY MARITIDE IN PEOPLE WITH TYPE 2 DIABETES SHOWED ROBUST, CLINICALLY MEANINGFUL REDUCTION IN BOTH HBA1C, WEIGHT

  • AMGEN: "LARGE MAJORITY" OF PEOPLE IN 52-WEEK MARITIDE EXTENSION STUDY GIVEN LOWER MONTHLY DOSE OR QUARTERLY DOSE OF DRUG MAINTAINED WEIGHT LOSS ACHIEVED IN PART 1 OF PHASE 2 TRIAL

  • AMGEN: SECOND YEAR OF MARITIDE TREATMENT VERY WELL TOLERATED INCLUDING AT QUARTERLY DOSES, WITH VERY LOW INCIDENCE OF NAUSEA, VOMITING & NO NEW SAFETY SIGNALS OBSERVED

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI